Evidence map›Paper›PMID 22847373›Full record

Trial reportThe journal of ECT2012

Rapid antidepressant effect of ketamine in the electroconvulsive therapy setting.

Chadi G Abdallah, Madonna Fasula, Ben Kelmendi, Gerard Sanacora, Robert Ostroff

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in The journal of ECT, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 7 pooled it
8.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 7 syntheses or guidelines pooled it, 121 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Ketamine as the anaesthetic for electroconvulsive therapy: the KANECT randomised controlled trial.The British journal of psychiatry : the journal of mental science · 2017
    Trial
  10. Trial
  11. Review
  12. Article
  13. Enduring effects of adolescent ketamine exposure on cocaine- and sucrose-induced reward in male and female C57BL/6 mice.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2020
    Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Ketamine and depression: a narrative review.Drug design, development and therapy · 2019
    Review
  19. A review of ketamine's role in ECT and non-ECT settings.Neuropsychiatric disease and treatment · 2018
    Review
  20. S -ketamine compared to etomidate during electroconvulsive therapy in major depression.European archives of psychiatry and clinical neuroscience · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 2 countries.

Chadi G AbdallahDepartment of Psychiatry and the Ribicoff Research Facilities, Yale University School of Medicine, New Haven, CT, USA.
Madonna Fasula
Ben Kelmendi
Gerard Sanacora
Robert Ostroff
Johnson & Johnson (United States) · US

Funding

Neuroimaging Sciences Training ProgramT32DA022975 · NIDA · YALE UNIVERSITY · PI Graeme F Mason, Rajita Sinha · 2007 to 2026
$5.7M
Studies of Amino Acid Neurotransmitter Contributions to DepressionK02MH076222 · NIMH · YALE UNIVERSITY · PI SANACORA, GERARD · 2006 to 2010
$634k
NIDA NIH HHS T32 DA022975NIDA NIH HHS T32-DA022975NIMH NIH HHS K02 MH076222
6 · The paper itself

Abstract

objectivesStudies now provide strong evidence that the N-methyl-D-aspartate receptor antagonist ketamine possesses rapidly acting antidepressant properties. This study aimed to determine if a low dose of ketamine could be used to expedite and augment the antidepressant effects of electroconvulsive therapy (ECT) treatments in patients experiencing a severe depressive episode. MATERIALS AND

methodsSubjects with major depressive disorder or bipolar disorder referred for ECT treatment of a major depressive episode were randomized to receive thiopental alone or thiopental plus ketamine (0.5 mg/kg) for anesthesia before each ECT session. The Hamilton Depression Rating Scale (HDRS) was administered at baseline and at 24 to 72 hours after the first and sixth ECT sessions.

resultsElectroconvulsive therapy exerted a significant antidepressant effect in both groups (F2,24 = 14.35, P < 0.001). However, there was no significant group effect or group-by-time interaction on HDRS scores. In addition, post hoc analyses of the time effect on HDRS showed no significant HDRS reduction after the first ECT session for either group.

conclusionsThe results of this pilot study suggest that ketamine, at a dose of 0.5 mg/kg, given just before ECT, did not enhance the antidepressant effect of ECT. Interestingly, the results further suggest that the coadministration of ketamine with a barbiturate anesthetic and ECT may attenuate the immediate antidepressant effects of the N-methyl-D-aspartate antagonist.

Indexed as

AnesthesiaElectroconvulsive TherapyAdolescentAdultAgedAnesthetics, DissociativeAntidepressive AgentsBipolar DisorderCombined Modality TherapyDepressionElectroencephalographyFemaleHumansHypnotics and SedativesKetamineMajor Depressive DisorderAnesthetics, DissociativeAntidepressive AgentsHypnotics and SedativesKetamineThiopental

Identifiers

PMID22847373
PMCPMC3426617
OpenAlexW2072783547

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.